BI-4020


Catalog No. Size PriceQuantity
M12190-10 Contact sales@xcessbio.com for quotation $100
M12190-C Contact sales@xchem.com for quotation $100
M12190-2 2 mg solid $660

Description

BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties.

Product information

CAS Number: 2664214-60-0

Molecular Weight: 542.68

Formula: C30H38N8O2

Chemical Name: (11R)-5, 11, 26-trimethyl-16-[(4-methylpiperazin-1-yl)methyl]-7-oxa-4, 5, 13, 20, 22, 27-hexaazapentacyclo[22.3.1.0, .0, .0, ]octacosa-1(28), 2(6), 3, 14(19), 15, 17, 21, 24, 26-nonaen-23-one

Smiles: CC1=CC2=CC(=N1)C1C=NN(C)C=1OCCC[C@@H](C)CN1C(NC3=CC=C(CN4CCN(C)CC4)C=C13)=NC2=O |t:41|

InChiKey: AIQBYZOTCIQTGW-HXUWFJFHSA-N

InChi: InChI=1S/C30H38N8O2/c1-20-6-5-13-40-29-24(17-31-36(29)4)26-16-23(14-21(2)32-26)28(39)34-30-33-25-8-7-22(15-27(25)38(30)18-20)19-37-11-9-35(3)10-12-37/h7-8,14-17,20H,5-6,9-13,18-19H2,1-4H3,(H,33,34,39)/t20-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 250 mg/mL (460.68 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

BI-4020 inhibits p-EGFR del19 T790M C797S with an IC50 of 0.6 nM.

In Vivo:

BI-4020 leads to tumor regressions in the human PC-9 (EGFR del19 T790M C797S) triple mutant NSCLC xenograft model in mice.

References:

  1. Engelhardt H,et al. Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors. J Med Chem. 2019 Nov 5.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed